What Astera Labs (ALAB)'s Scorpio P-Series Surge and Big Tech Partnerships Mean for Shareholders

• Astera Labs recently reported that its Scorpio P-Series switches, which entered volume production in the second quarter of 2025, have become its fastest-growing product line and now contribute over 10% of total revenues.
• This surge is further supported by collaborations with major industry players, including NVIDIA, AMD, and Alchip Technologies, solidifying Astera Labs’ role in advancing data center connectivity for AI infrastructure.
• We’ll explore how the rapid growth of the Scorpio P-Series and key partnerships could influence Astera Labs’ long-term investment outlook.

This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

Astera Labs Investment Narrative Recap

To be a shareholder in Astera Labs, you need to believe in the long-term adoption of AI infrastructure and the company’s ability to remain a leading provider of connectivity solutions for hyperscale data centers. The recent surge in Scorpio P-Series switch revenues, now over 10% of total sales, and expanded partnerships, while encouraging, primarily strengthen near-term growth catalysts and do not fundamentally change the core risks of customer concentration and competition from integrated solutions by larger chipmakers.

Among recent announcements, the launch of the PCIe 6 connectivity portfolio for AI platforms directly relates to the Scorpio P-Series' success and highlights Astera Labs’ commitment to innovation as a driver for further market penetration. This reinforces the current catalysts of product and customer diversification, which are crucial for supporting revenue growth and maintaining differentiation as adoption accelerates.

On the other hand, investors should be aware that any shift in hyperscaler purchasing patterns or migration towards integrated solutions could...

Read the full narrative on Astera Labs (it's free!)

Astera Labs' outlook anticipates $1.5 billion in revenue and $393.5 million in earnings by 2028. This is based on a forecasted annual revenue growth of 34.1% and an increase in earnings of $293.3 million from the current $100.2 million.

Uncover how Astera Labs' forecasts yield a $175.44 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Twenty-six members of the Simply Wall St Community put Astera Labs’ fair value anywhere from US$15.98 to US$209.88 per share. With product launches fueling rapid revenue growth, investor outlooks remain highly varied, underscoring the importance of understanding both catalysts and competition when considering the company’s future.

Explore 26 other fair value estimates on Astera Labs - why the stock might be worth less than half the current price!

Build Your Own Astera Labs Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Astera Labs research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Astera Labs research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Astera Labs' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com